Relapse Risk Assessment for Schizophrenia Patients (RASP): a New Self-Report Screening Tool.

CONCLUSION: The reliability and validity data presented support the use of RASP in settings where addition of a brief self-report assessment of relapse risk among patients with schizophrenia may be of benefit. Ease of use and scoring and the ability to administer without clinical supervision allows for routine administration and assessment of relapse risk. PMID: 29164930 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29164930?dopt=Abstract

Source: Clinical Schizophrenia and Related Psychoses - November 23, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

More News: Anxiety | Schizophrenia